Growth_NN
regulation_NN
and_CC
cellular_JJ
changes_NNS
during_IN
differentiation_NN
of_IN
human_JJ
prostatic_JJ
cancer_NN
LNCaP_NN
cells_NNS
as_IN
induced_VBN
by_IN
T_NN
lymphocyte_NN
-_:
conditioned_JJ
medium_NN
._.

Human_JJ
prostatic_JJ
epithelial_JJ
cells_NNS
from_IN
an_DT
androgen-dependent_JJ
LNCaP_NN
cell_NN
line_NN
were_VBD
examined_VBN
in_IN
response_NN
to_TO
conditioned_JJ
medium_NN
-LRB-_-LRB-
CM_NN
-RRB-_-RRB-
derived_VBN
from_IN
phytohemagglutinin_NN
-LRB-_-LRB-
PHA_NN
-RRB-_-RRB-
-_:
stimulated_JJ
lymphocytes_NNS
._.

Addition_NN
of_IN
CM_NN
caused_VBD
a_DT
greater_JJR
than_IN
70_CD
%_NN
reduction_NN
of_IN
cell_NN
proliferation_NN
by_IN
cell_NN
counting_NN
and_CC
cell_NN
cycle_NN
._.

These_DT
cells_NNS
showed_VBD
G1_NN
phase_NN
arrest_NN
and_CC
the_DT
clonogenicity_NN
was_VBD
reduced_VBN
._.

The_DT
growth-modulating_JJ
effect_NN
was_VBD
dose-dependent_JJ
and_CC
not_RB
due_JJ
to_TO
cell_NN
lysis_NN
or_CC
apoptosis_NN
._.

The_DT
binding_NN
of_IN
androgen_NN
to_TO
androgen_NN
receptor_NN
on_IN
these_DT
cells_NNS
showed_VBD
approximately_RB
50_CD
%_NN
reduction_NN
,_,
underlining_VBG
a_DT
proliferation_NN
reduction_NN
mechanism_NN
._.

The_DT
prostate-specific_JJ
antigen_NN
-LRB-_-LRB-
PSA_NN
-RRB-_-RRB-
was_VBD
downregulated_VBN
to_TO
approximately_RB
75_CD
%_NN
during_IN
the_DT
process_NN
._.

Cell_NN
morphology_NN
showed_VBD
dendritic_JJ
processes_NNS
extending_VBG
from_IN
cytoplasm_NN
and_CC
other_JJ
neuroendocrine_JJ
cell_NN
characteristics_NNS
._.

The_DT
expression_NN
of_IN
several_JJ
cytoskeleton_NN
and_CC
intracellular_JJ
proteins_NNS
increased_VBD
as_IN
determined_VBN
by_IN
immunostaining_NN
on_IN
slides_NNS
and_CC
by_IN
ELISA_NN
procedures_NNS
._.

These_DT
included_VBD
vimentin_NN
,_,
correlating_VBG
to_TO
cell_NN
shape_NN
changes_NNS
,_,
cytokeratins_NNS
8_CD
and_CC
18_CD
,_,
associated_VBN
with_IN
differentiated_VBN
cell_NN
types_NNS
of_IN
prostate_NN
epithelia_NN
,_,
and_CC
neuron-specific_JJ
enolase_NN
and_CC
serotonin_NN
,_,
associated_VBN
with_IN
neuroendocrine_JJ
cells_NNS
._.

From_IN
these_DT
cellular_JJ
changes_NNS
,_,
we_PRP
can_MD
infer_VB
that_IN
the_DT
cell_NN
growth_NN
was_VBD
modulated_VBN
along_IN
with_IN
induction_NN
of_IN
terminal_JJ
differentiation_NN
._.

Activated_VBN
T_NN
cells_NNS
were_VBD
demonstrated_VBN
to_TO
be_VB
important_JJ
in_IN
providing_VBG
the_DT
modulating_VBG
activity_NN
._.

This_DT
growth_NN
modulator_NN
was_VBD
semipurified_VBN
and_CC
had_VBD
an_DT
estimated_VBN
molecular_JJ
weight_NN
13,000_CD
to_TO
24,000_CD
Da_NN
._.

The_DT
activity_NN
was_VBD
determined_VBN
to_TO
be_VB
distinct_JJ
from_IN
TGF_NN
,_,
TNF_NN
,_,
and_CC
some_DT
commonly_RB
known_VBN
lymphokines_NNS
._.

The_DT
interaction_NN
between_IN
lymphoid_JJ
and_CC
prostatic_JJ
cells_NNS
in_IN
growth_NN
and_CC
development_NN
is_VBZ
described_VBN
._.

